Search
News

News

Main Indications and Applications of CO₂ Fractional Laser
Date : 2026-10-29 Click count : 184

Main Indications and Applications of CO₂ Fractional Laser

The core principle of CO₂ fractional laser is to create numerous microscopic thermal zones (MTZs) in the skin using a 10600nm wavelength, while preserving surrounding normal tissue as a “repair reservoir.” These controlled micro-injuries trigger the skin’s wound-healing cascade, stimulate collagen neogenesis and remodeling, and thereby achieve multi-level effects ranging from “lesion removal” to “skin texture reconstruction.” Its indications are correspondingly broad—from scar revision, which has the most robust evidence, to precise vaporization of superficial benign lesions, and to recent exploration in gynecologic mucosal applications—all supported by varying levels of clinical evidence.

 

Scar Revision: The Core Area with the Strongest Evidence

This is the most established and most extensively studied direction for CO₂ fractional laser.

 

Surgical scars. A systematic review and meta-analysis of 14 controlled trials involving 492 participants demonstrated clear efficacy of fractional CO₂ laser for surgical scars. Notably, the timing of treatment initiation matters: starting treatment within 1 month after surgery produced significantly better improvement than starting after 3 months. This suggests that early intervention may lead to better outcomes for surgical scars.

 

Atrophic acne scars. Fractional CO₂ laser is an important reference standard for acne scar treatment. A systematic review and meta-analysis comparing fractional CO₂ laser with microneedling-based modalities showed comparable overall scar score improvement, but CO₂ laser had a significant advantage in “categorical treatment success.” Objectively, CO₂ laser carries a significantly higher risk of post-inflammatory hyperpigmentation (PIH) than standard microneedling—a factor that must be weighed in clinical decision-making.

 

Hypertrophic scars. A meta-analysis of 10 randomized controlled trials involving 248 patients and 300 scars showed that fractional CO₂ laser significantly reduced the total Vancouver Scar Scale (VSS) score, supporting its evidence-based value for burn, traumatic, and post-surgical hypertrophic scars.

 

An “added value” in scar management: transdermal drug delivery. The regular microchannels created by the fractional mode on the scar surface also serve as entry points for drug delivery. Fractional CO₂ laser combined with topical triamcinolone acetonide can achieve outcomes comparable to intralesional injection in improving scars, without the hypopigmentation and local lipoatrophy commonly associated with steroid injections—though more treatment sessions may be required. This characteristic gives CO₂ fractional laser a synergistic role beyond “photoelectric therapy alone” in comprehensive scar management.

 

Skin Rejuvenation and Texture Improvement

CO₂ fractional laser improves photoaging-related fine lines, wrinkles, skin laxity, and enlarged pores. Its combination of “ablation and thermal remodeling” provides a depth effect that non-ablative lasers cannot easily replace in improving structural wrinkles and skin texture. Clinically, it can also address comprehensive texture concerns including roughness, color, elasticity, and pores.

 

It should be noted that for individuals whose primary concern is “minimizing pores and improving skin texture” and who are unwilling to accept a longer recovery period, clinicians often weigh ablative versus non-ablative options. The advantage of CO₂ fractional laser lies in “depth,” not “zero downtime.”

 

Benign Skin Lesions and Cutaneous Growths

The precise vaporization capability of CO₂ laser allows direct removal of various superficial benign growths. According to clinical reports, indications include seborrheic keratosis, syringoma, xanthelasma, sebaceous hyperplasia, milia, skin tags, verruca vulgaris, flat warts, and pigmented nevi. These applications rely more on the vaporization properties of CO₂ laser, which differs from the “thermal stimulation” logic of fractional mode in scar and rejuvenation treatments—but both can be achieved on the same device through mode switching.

 

Extended Applications in Gynecology and Mucosal Areas (Requires Strict Evaluation)

In recent years, evidence for fractional CO₂ laser in gynecology has been gradually accumulating, primarily in genitourinary syndrome of menopause (GSM) —related vaginal dryness and dyspareunia, as well as vaginal laxity and certain vulvar conditions. The mechanism involves delivering controlled thermal energy to the vaginal mucosa, creating micro-injuries that stimulate collagen synthesis and restore tissue elasticity—positioning it as a minimally invasive option for vaginal rejuvenation in menopausal women with GSM.

 

However, the maturity of evidence in this field is not comparable to that of dermatologic indications. Results from randomized controlled trials are inconsistent, and some sham-controlled trials have failed to confirm significant improvement of GSM symptoms with CO₂ laser. Therefore, gynecologic applications must be implemented after strict evaluation of indications by specialist physicians and should not be regarded as a routine option in general aesthetic practice.

 

An Unavoidable Safety Prerequisite: PIH Risk in Darker Skin Types

The “broad indications” of CO₂ fractional laser absolutely do not mean it can be used indiscriminately. The strong water absorption at 10600nm means extremely high procedural precision is required.

 

The risk of post-inflammatory hyperpigmentation (PIH) in darker skin types (Fitzpatrick IV–VI) must be taken seriously. Data show that the incidence of PIH with fully ablative CO₂ laser in darker skin exceeds 37%, and darker skin types (IV–VI) account for up to 62% of laser-related PIH cases. Although fractional mode significantly reduces scarring risk, it does not completely eliminate the possibility of PIH. By contrast, some fractional CO₂ laser protocols using specific low-energy settings have observed no PIH in type IV–V skin—indicating that individualized parameter strategy is the key variable.

 

This means that clinical decision-making for CO₂ fractional laser must simultaneously answer three questions: Is the nature of the lesion suitable for CO₂ laser? Does the patient’s skin type allow a sufficient risk window? Can the parameter settings achieve a balance between efficacy and safety? The assessment of endpoint responses and energy control always defines the safety boundary.